El asma necesita nuevas drogas

agonist has a modest effect in the allergen challenge model in asthma: a randomised controlled trial. Respir Med 2010;104(5):668–74

38. Reber L, Da Silva CA, Frossard N. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur J Pharmacol 2006;533(1–3):327–40
39. Denyer J, Patel V. Syk kinase inhibitors in allergic diseases. Drug News Perspect 2009;22(3):146–50
40. Stenton GR, Ulanova M, Déry RE. Inhibition of allergic inflammation in the airways using aerosolized antisense to Syk kinase. J Immunol 2002;169(2):1028–36
41. Compalati E, Passalacqua G, Bonini M, Canonica GW. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy 2009;64(11):1570–9
42. Campbell JD, Buckland KF, McMillan SJ. Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J Exp Med 2009;206(7):1535–47
43. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006;5(6):471–84
44. Gauvreau GM, Hessel EM, Boulet LP, Coffman RL, O’Byrne PM. Immunostimulatory sequences regulate interferon-inducible genes but not allergic airway responses. Am J Respir Crit Care Med 2006;174(1):15–20
45. Creticos PS, Schroeder JT, Hamilton RG; Immune Tolerance Network Group. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006;355(14):1445–55
46. Ozdemir C, Akdis M, Akdis CA. T regulatory cells and their counterparts: masters of immune regulation. Clin Exp Allergy 2009;39(5):626–39
47. Xystrakis E, Kusumakar S, Boswell S. Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. J Clin Invest 2006;116(1):146–55
48. Hammad H, Lambrecht BN. Dendritic cells and epithelial cells: linking innate and adaptive immunity in asthma.Nat Rev Immunol 2008;8(3):193–204
49. Idzko M, Hammad H, van Nimwegen M. Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function. J Clin Invest 2007;117(2):464–72
50. Idzko M, Hammad H, van Nimwegen M. Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function. J Clin Invest 2006;116(11):2935–44
51. Barnes PJ. Emerging pharmacotherapies for COPD. Chest 2008;134(6):1278–86